Madrigal Pharmaceuticals

Valuation Analysis

About the Company

Madrigal Pharmaceuticals en bref

Madrigal Pharmaceuticals (MDGL) is currently trading at 405,17 € with a market capitalization of 9,4 Md €. The 52-week range spans from 259,38 € to 533,21 €; the current price is 24% below the yearly high. Year-over-year revenue growth stands at +71.2%.

💰 Dividende

Madrigal Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent Madrigal Pharmaceuticals (MDGL) au consensus : Achat Fort. L'objectif de cours moyen est de 592,10 €, soit un potentiel de +46.14% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 470,78 € à 834,06 €.

Madrigal Pharmaceuticals : la thèse d'investissement en détail

Madrigal Pharmaceuticals (MDGL) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 71.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 91.48%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 46.14% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 10.52% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The analyst consensus price target implies 46.14% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to elevated short interest (10.52%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Madrigal Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.